Pharmaceutical Strategy Analysis l Report Store l Pharma Intelligence

Triple Negative Breast Cancer KOL Interview

“It [Abraxane] is so easy to give. Women tolerate it so well. It works pretty good, it doesn’t work all the time, it works pretty well, and the patients don’t get so fatigued, they don’t have side effects, they don’t need premeds, and they rarely need to be boosted for white cells decrease. Whereas in the Eribulin, you know they’re gonna be coming back. It’s a pretty easy drug to give. Patients tolerate it fairly well… I use it [Abraxane] as first line and I go back to it. Even if I have somebody that progresses, if they’ve been off of it for a while, I will often even go back to it.”

Strategy analysis

Triple Negative Breast Cancer KOL Interview

Acute Lymphocytic Leukemia KOL Interview

Follicular Lymphoma KOL Interview

India Regulatory Issues

Inpatient Infections Pulse

GLP-1 Pulse Survey

SGLT-2 Pulse Survey

Indonesia Regulatory Issues

Indonesia Healthcare System Overview

Germany Regulatory Issues

US Pricing and Reimbursement

Germany Pricing and Reimbursement

France Regulatory Issues

Germany Healthcare System Overview

France Healthcare System Overview